AbbVie’s immunology franchise has delivered results far above earlier projections, with Skyrizi and Rinvoq now expected to jointly generate $38 billion in annual sales by 2030. In the fourth quarter of 2025, global net revenues from the immunology portfolio reached $8.63 billion, an 18.3 percent year-over-year increase. Skyrizi sales climbed 32.5 percent to $5.01 billion, while Rinvoq grew 29.5 percent to $2.37 billion, more than offsetting a 25.9 percent decline in Humira to $1.25 billion. These trends have prompted analysts to lift full-year 2026 profit forecasts and extend AbbVie’s immunology leadership well into the next decade.

Beyond immunology, AbbVie has strengthened its oncology and neuroscience pipelines through the acquisitions of ImmunoGen and Cerevel Therapeutics. In neuroscience, sales rose 17.9 percent in Q4 to $2.96 billion, led by Vraylar’s 10.5 percent gain to $1.02 billion and Botox Therapeutic growth of 13.4 percent to $991 million. Oncology generated $1.66 billion in Q4 revenues, with Venclexta up 8.6 percent to $711 million, even as Imbruvica declined 20.8 percent to $671 million. The ImmunoGen deal adds next-generation antibody-drug conjugates targeting solid tumors, while Cerevel’s portfolio enhances AbbVie’s presence in CNS disorders, positioning the company for diversified growth beyond blockbuster immunology drugs.

Analysts forecast AbbVie will achieve a 6.6 percent compound annual sales growth rate and a 7.7 percent EPS CAGR through 2030, outpacing most large-cap peers. In Q4 2025, adjusted EPS rose 25.5 percent to $2.71, exceeding consensus estimates by 2.3 percent. The company issued 2026 guidance of $14.37–$14.57 in adjusted EPS, above the street’s $14.24 estimate, and projects sustained double-digit growth in immunology while leveraging margin contributions from newly acquired assets. Continued dividend increases—recently marking more than five decades of hikes—and a robust free cash flow profile further support shareholder returns and flexibility for future M&A.